My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.
It's actually more common than you'd think. According to the article, Fabry disease occurs in one person per 40,000. But from my own research (ala Google), I know it affects about one in every 40,000 to 60,000 men worldwide. It can affect women as well but the prevalence is unknown.
Latest Comments
5 Best Large Caps
All good picks!
Technically Speaking: COT Positioning – Back To Extremes: Q2-2020
Completely agree.
Protalix BioTherapeutics Pipeline Progress
My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.
Protalix BioTherapeutics Pipeline Progress
It's actually more common than you'd think. According to the article, Fabry disease occurs in one person per 40,000. But from my own research (ala Google), I know it affects about one in every 40,000 to 60,000 men worldwide. It can affect women as well but the prevalence is unknown.
Changing The Way We Fight Covid-19
Like these articles that really make one think and reexamine our preconceived notions.
This Is How It’s Supposed To Work
Are we sure they aren't? I had thought the US government were pursuing both.
Coronavirus: Let's Move On
Very interesting comment thread, thanks.
Will The US Economic Rebound Continue?
Agreed.
Avoid These 2 Stocks In July
Yes, timing is key.
Empowering America
Well said Joseph.